Case Study: Serotiny achieves faster discovery of multi-domain proteins for next-generation cell and gene therapies with Benchling

Accelerating the discovery of multidomain proteins for next-generation cell and gene therapies

Serotiny is a South San Francisco–based biotech (11–50 employees) that designs high‑throughput, multi‑domain proteins for next‑generation cell and gene therapies targeting cancers and genetic disorders. The team struggled with fragmented Microsoft tools and legacy molecular design software that made it hard to find samples or past results, forced repetitive administrative work, and created error‑prone copy/paste workflows that slowed research and limited computational analysis.

By adopting Benchling’s centralized, cloud‑based platform for sequence design, sample management and experimental records (with API access), Serotiny created a single source of truth that enables real‑time collaboration between wet‑lab and computational teams, global search across experiments, and structured, traceable data. The result was improved data quality and faster time to insight, the ability to ask new computational questions, increased collaboration and visibility, and a 3× expansion of their Benchling footprint in one year.

Serotiny

Diego Vargas

Senior Director of Research